Loading...
•
Dec 31, 2019
BioCryst Q4 2019 Earnings Report
BioCryst reported Q4 2019 financial results, highlighted by increased revenues driven by Torii upfront payment and RAPIVAB sales, and provided a corporate update.
Key Takeaways
BioCryst's Q4 2019 total revenues increased significantly to $39.7 million compared to $2.7 million in Q4 2018, primarily due to the recognition of revenue from the Torii commercialization rights agreement and RAPIVAB product sales. The net loss for the quarter was $2.6 million, a substantial improvement from the $27.4 million loss in the same period of the previous year.
Total revenues increased to $39.7 million, driven by Torii upfront payment and RAPIVAB sales.
R&D expenses increased to $26.8 million due to investment in complement-mediated diseases program.
SG&A expenses increased to $10.5 million, supporting commercial activities for berotralstat launch.
Net loss improved to $2.6 million, compared to a net loss of $27.4 million in Q4 2018.
Forward Guidance
BioCryst expects full year 2020 net operating cash use to be in the range of $125 to $150 million, and its operating expenses to be in the range of $135 to $160 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...